Wall Street is chewing over data on Amgen’s weight loss injection, MariTde. Meanwhile, GE HealthCare will acquire a Japanese ...

Patients self-administer the drug using a pre-dosed injector pen, but Lilly recently introduced the product in single-dose ...

Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.

Eli Lilly and Company announced earlier this week that its popular obesity drug, Zepbound (tirzepatide) outperformed rival ...

Leptin by itself doesn't hold promise for weight loss — but a new mouse study suggests it could work in combination with ...

BioAge (BIOA) stock cratered 70% Friday evening after the company said it was discontinuing a Phase 2 study for its ...

It is not clear what specifically the new facility will produce, though Amgen could be ramping up its manufacturing capacity ...

Biopharma company Amgen plans to add 370 jobs as part of a new, $1.02 billion investment in Holly Springs. It’s the latest ...

Eli Lilly ( NYSE:LLY) has been making headlines recently with its weight-loss drug Zepbound (tirzepatide). Eli Lilly's weight ...

Health care stocks have underperformed in recent months on uncertainty surrounding the incoming Donald Trump administration, but they can often be a solid defensive play in an uncertain economy.

Furthermore, the biotech's dividend program remains compelling despite near-term headwinds. Therefore, Amgen's combination of ...

That increased convenience will have to be accompanied by weight loss that is at least as effective as its rivals, and Amgen reckons it has achieved that with an average 20% reduction in body ...